OABI — OmniAb, Inc.
$4.66-2.51%
Last close: · regular session
After-hours $4.66 0.00% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for OABI in the TickerWise workspace.
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 114
- Website: https://www.omniab.com
Latest SEC filings for OABI
Latest OABI news
- OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth Read article
- OmniAb, Inc. (OABI) Analyst/Investor Day Transcript Read article
- All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy Read article
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day Read article
- Bank of America Corp DE Acquires 149,493 Shares of OmniAb, Inc. $OABI Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.